000 01604 a2200433 4500
005 20250515172542.0
264 0 _c20090918
008 200909s 0 0 eng d
022 _a1557-3125
024 7 _a10.1158/1541-7786.MCR-08-0519
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMcNeill, Daniel R
245 0 0 _aImpairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
_h[electronic resource]
260 _bMolecular cancer research : MCR
_cJun 2009
300 _a897-906 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
650 0 4 _aAnimals
650 0 4 _aAntimetabolites, Antineoplastic
_xpharmacology
650 0 4 _aAntineoplastic Agents, Alkylating
_xpharmacology
650 0 4 _aApoptosis
_xdrug effects
650 0 4 _aCHO Cells
650 0 4 _aCell Cycle
_xdrug effects
650 0 4 _aCell Survival
_xdrug effects
650 0 4 _aCricetinae
650 0 4 _aCricetulus
650 0 4 _aDNA Repair
650 0 4 _aDNA-(Apurinic or Apyrimidinic Site) Lyase
_xbiosynthesis
650 0 4 _aFluorouracil
_xpharmacology
650 0 4 _aG1 Phase
_xdrug effects
650 0 4 _aHumans
650 0 4 _aMutation
650 0 4 _aNeoplasms
_xdrug therapy
700 1 _aLam, Wing
700 1 _aDeWeese, Theodore L
700 1 _aCheng, Yung-Chi
700 1 _aWilson, David M
773 0 _tMolecular cancer research : MCR
_gvol. 7
_gno. 6
_gp. 897-906
856 4 0 _uhttps://doi.org/10.1158/1541-7786.MCR-08-0519
_zAvailable from publisher's website
999 _c18896301
_d18896301